Markets:

Overview

News

Currencies

International

Treasuries

Immatics N.V. - Ordinary Shares (NQ:IMTX)

11.52 +0.17 (+1.45%)

Streaming Delayed Price Updated: 10:27 AM EDT, Apr 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Immatics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >

Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs

June 02, 2022

From Bristol Myers Squibb

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Immatics: Q2 Earnings Insights ↗

August 10, 2021

Shares of Immatics (NASDAQ:IMTX) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 21.62% year over year to ($0.45), which...

Via Benzinga

Immatics Initiates Phase 1 Clinical Trial of IMA401 in Advanced Solid Tumors ↗

May 10, 2022

Immatics N.V. (NASDAQ: IMTX) announced the initiation of a Phase 1 clinical trial of its drug candidate IMA401 for patients with recurrent and/or refractory solid tumors.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

March 16, 2022

On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

January 25, 2022

On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap...

Via Benzinga

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

December 14, 2021

From Bristol Myers Squibb

Via Business Wire

Immatics Unveils Early-Stage Data Of TCR-Engineered Cell Therapy In Solid Tumors ↗

November 09, 2021

Immatics N.V. (NASDAQ: IMTX) announced an interim clinical data update from its TCR-engineered cell therapy (TCR-T) approach ACTengine IMA203 targeting PRAME....

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 12, 2021

Gainers SCWorx (NASDAQ:WORX) shares rose...

Via Benzinga

BioCopy, Immatics Team Up For Characterization Of TCR-Peptide-HLA Interactions ↗

July 07, 2021

Switzerland-based BioCopy AG has collaborated with Immatics N.V. (NASDAQ: IMTX) to characterize T cell receptors (TCRs). T cell receptors and...

Via Benzinga

14 Biotech Stocks To Watch Over The Next 6 Months ↗

June 23, 2021

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks. A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 04, 2021

Gainers Obalon Therapeutics (NASDAQ:OBLN)...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.